| Bioactivity | Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits of CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A861 induces leukemia cell apoptosis, and has potent anti-leukemic activities[1]. | ||||||||||||
| Invitro | Casein Kinase inhibitor A86 is highly effective in inducing leukemia cell apoptosis at 160 nM or lower, mostly in correlation to their capacity to stabilize p53[1].Casein Kinase inhibitor A86 (0.08-2 μM; 6.5 hours) abolishes the expression of MYC, MDM2, and the anti-apoptotic oncogene MCL1. Casein Kinase inhibitor A86 induces a marked reduction in mRNA expression of MYC and MDM2, yet upregulates the expression of the Wnt targets AXIN2 and CCND1 (Cyclin D1)[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | Casein Kinase inhibitor A86 | ||||||||||||
| CAS | 2079069-01-3 | ||||||||||||
| Formula | C18H25FN6 | ||||||||||||
| Molar Mass | 344.43 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Casein Kinase inhibitor A86
CAS: 2079069-01-3 F: C18H25FN6 W: 344.43
Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.